Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (March 23rd Preview)
-
Lyme vaccine shows strong efficacy: Pfizer, Valneva vow regulatory push
Pfizer and Valneva said their Phase 3 Lyme disease vaccine reduced cases by roughly 70–73% but missed the trial’s pre-specified statistical threshold. The companies acknowledged lower-than-expected infection rates during the study that tightened confidence intervals and said they will pursue regulatory submissions despite the primary endpoint miss. Public statements from both firms emphasize a favorable safety profile alongside the efficacy signal. Regulators will need to weigh the magnitude of observed protection against the statistical shortfall; the companies plan to present full datasets and supportive analyses. The situation raises questions about how agencies interpret underpowered vaccine trials when event rates fall below projections. The development matters for prevention of Borrelia burgdorferi infections across the U.S. and Europe and could influence CDC advisory timelines if regulators opt to review the dossier. Company filings and STAT coverage reported the efficacy figure and the companies’ intent to seek approval.
-
Insmed eyes front-line expansion after Arikayce late‑stage win
Insmed reported a Phase 3 victory for Arikayce in treatment‑naïve patients with Mycobacterium avium complex (MAC) lung infection, meeting the trial’s primary goals and showing improved respiratory outcomes and culture conversion rates. The company said the results open the door to expanding Arikayce into earlier lines of care beyond the accelerated‑approval population it currently serves. The study, disclosed in company statements and STAT reporting, achieved prespecified endpoints for symptom improvement and microbiologic response. Arikayce was previously approved under accelerated approval for refractory MAC; the new data support broader label discussions with regulators and potential commercial upside. Analysts and management highlighted peak sales upside if Arikayce penetrates front‑line treatment, while payers and guideline groups will scrutinize comparative benefit and safety versus standard regimens.
-
Apogee’s long‑acting eczema drug promises less frequent dosing — rivals in sight
Apogee Therapeutics reported mid‑stage maintenance data showing its anti‑IL‑13 candidate induced durable skin and itch relief with far less frequent injections than current biologics. In the Phase 2 maintenance readout, zumilokibart achieved high EASI‑75 rates at one year with dosing intervals of three and six months, figures the company highlighted in a STAT briefing and its press release. Specifically, the trial showed roughly 75% of participants dosed every three months and 85% dosed every six months maintained a 75% improvement in EASI scores at one year. Apogee framed the results as potentially offering a convenience and adherence advantage versus Regeneron/Sanofi’s Dupixent and Lilly’s Ebglyss, but stressed confirmatory larger studies are required. The data triggered analyst attention and debate about commercial positioning: if replicated, less‑frequent injectable regimens could reshape maintenance strategies for moderate‑to‑severe atopic dermatitis.
-
Novartis buys Pikavation for up to $3B — bolsters PI3Kα cancer push
Novartis agreed to acquire Pikavation Therapeutics for up to $3 billion to add SNV4818, a mutant‑selective PI3Kα inhibitor, to its oncology pipeline. Novartis said SNV4818 aims to selectively inhibit tumor‑mutant PI3Kα while sparing wild‑type enzyme, a design intended to reduce tolerability issues that limit earlier PI3Kα inhibitors. The deal accelerates Novartis’ strategy to target PIK3CA‑mutated HR+/HER2‑ breast cancer and to enable earlier‑line combinations with hormonal agents. Pikavation’s program is in Phase I/II testing and has shown preclinical selectivity and activity across common PIK3CA mutations. Novartis framed the acquisition as precision‑medicine extension that could improve combination tolerability and dosing consistency versus older non‑selective PI3Kα agents, a company executive said in the announcement.
-
Sanofi inks $1.2B deal for Kali trispecific — $180M upfront signals renewed T‑cell bet
Sanofi struck a partnership to license a Phase 1‑stage trispecific T‑cell engager from Kali Therapeutics, paying $180 million upfront and structuring the broader pact at up to $1.2 billion. The move marks Sanofi’s re‑entry into the T‑cell engager space and highlights large pharmas’ appetite for multispecific platforms that can redirect T‑cells to tumors. Kali’s trispecific is designed to engage T cells with improved tumor targeting; Sanofi said the asset complements its immuno‑oncology ambitions. Company statements noted the upfront and near‑term payments would support clinical expansion and translational studies in California‑based Kali. The deal underscores continued strategic interest in T‑cell engagers despite prior waves of partnership activity and varying clinical readouts across the modality.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.